NO20074052L - Prosesser for a fremstille pyrazol[3,4-D]pyrimidinetere - Google Patents

Prosesser for a fremstille pyrazol[3,4-D]pyrimidinetere

Info

Publication number
NO20074052L
NO20074052L NO20074052A NO20074052A NO20074052L NO 20074052 L NO20074052 L NO 20074052L NO 20074052 A NO20074052 A NO 20074052A NO 20074052 A NO20074052 A NO 20074052A NO 20074052 L NO20074052 L NO 20074052L
Authority
NO
Norway
Prior art keywords
processes
preparing pyrazole
pyrimidine
pyrimidine ethers
ethers
Prior art date
Application number
NO20074052A
Other languages
English (en)
Norwegian (no)
Inventor
Tawfik Gharbaoui
Dipanjan Sengupta
Edward A Lally
Naomi S Kato
Marlon Carlos
Natalie Rodriguez
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of NO20074052L publication Critical patent/NO20074052L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20074052A 2005-01-13 2007-08-06 Prosesser for a fremstille pyrazol[3,4-D]pyrimidinetere NO20074052L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64371205P 2005-01-13 2005-01-13
PCT/US2006/001020 WO2006076455A2 (en) 2005-01-13 2006-01-12 Processes for preparing pyrazolo[3,4-d]pyrimidine ethers

Publications (1)

Publication Number Publication Date
NO20074052L true NO20074052L (no) 2007-09-12

Family

ID=36463499

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074052A NO20074052L (no) 2005-01-13 2007-08-06 Prosesser for a fremstille pyrazol[3,4-D]pyrimidinetere

Country Status (22)

Country Link
US (1) US7425630B2 (enExample)
EP (1) EP1838713A2 (enExample)
JP (1) JP2008526975A (enExample)
KR (1) KR20070114126A (enExample)
CN (1) CN101142216A (enExample)
AR (1) AR052557A1 (enExample)
AU (1) AU2006204940A1 (enExample)
BR (1) BRPI0606115A2 (enExample)
CA (1) CA2593345A1 (enExample)
CR (1) CR9224A (enExample)
DO (1) DOP2006000009A (enExample)
EA (1) EA013968B1 (enExample)
GT (1) GT200600011A (enExample)
HN (1) HN2006001493A (enExample)
IL (1) IL184365A0 (enExample)
MX (1) MX2007008381A (enExample)
NO (1) NO20074052L (enExample)
PA (1) PA8659701A1 (enExample)
PE (1) PE20061118A1 (enExample)
TW (1) TW200637865A (enExample)
WO (1) WO2006076455A2 (enExample)
ZA (1) ZA200705279B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE602004009295T2 (de) 2003-01-14 2008-07-03 Arena Pharmaceuticals, Inc., San Diego 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
EP2292620A3 (en) * 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prohylaxis and treatment of disorders related thereto
US7923465B2 (en) * 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
JP5498392B2 (ja) 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
US8822480B2 (en) 2008-07-16 2014-09-02 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and use thereof as GPR119 modulators
WO2010026214A1 (en) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines and their use for the treatment of cns disorders
DK2414363T3 (da) 2009-03-31 2014-01-27 Boehringer Ingelheim Int 1-heterocyklyl-1,5-dihydro-pyrazol[3,4-d]pyrimidin-4-on-derivater og anvendelse af disse som PDE9A-modulatorer.
US20100285145A1 (en) * 2009-05-08 2010-11-11 Pfizer Inc Gpr 119 modulators
NZ596467A (en) * 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
SG10201500639TA (en) 2010-01-27 2015-03-30 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
WO2012020022A1 (en) 2010-08-12 2012-02-16 Boehringer Ingelheim International Gmbh 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
PH12013500547A1 (en) 2010-09-22 2013-06-10 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
EA031618B1 (ru) 2011-06-09 2019-01-31 Ризен Фармасьютикалз Са Соединения-модуляторы gpr-119
JP6567276B2 (ja) 2014-05-13 2019-08-28 ソニーセミコンダクタソリューションズ株式会社 固体撮像素子、および電子機器
HK1243936A1 (zh) * 2014-12-06 2018-07-27 Intra-Cellular Therapies, Inc. 有机化合物
ES2995737T3 (en) 2015-01-06 2025-02-11 Arena Pharm Inc Compound for use in treating conditions related to the s1p1 receptor
MA42807A (fr) 2015-06-22 2018-07-25 Arena Pharm Inc Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
JP2019122134A (ja) 2018-01-04 2019-07-22 Ntn株式会社 スイッチング電源の力率改善用ｐｗｍ制御装置
EP3801459B1 (en) 2018-06-06 2024-08-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CA3219597A1 (en) * 2021-06-23 2022-12-29 F. Hoffmann-La Roche Ag Novel process

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3070304D1 (en) 1980-04-28 1985-04-25 Teijin Ltd Thiazolo(3,2-a)pyrimidine derivatives, process for preparing same, and drug containing same
EP0053678A1 (de) 1980-12-05 1982-06-16 BASF Aktiengesellschaft 5-Amino-1-phenyl-4-cyanpyrazole, diese enthaltende herbizide Mittel, Verfahren zu ihrer Herstellung und ihre Anwendung als Herbizide
US4612376A (en) 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
JP4022271B2 (ja) * 1995-10-31 2007-12-12 富士フイルム株式会社 ピラゾリルアゾフエノール色素
DE60004685T2 (de) * 1999-09-17 2004-07-29 Abbott Gmbh & Co. Kg Pyrazolopyrimidine als arzneimittel
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
DE10219435A1 (de) * 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituierte Pyrazolo-pyrimidin-4-one
WO2004009602A1 (en) * 2002-07-23 2004-01-29 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
EP2292620A3 (en) * 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prohylaxis and treatment of disorders related thereto
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
EA013968B1 (ru) 2010-08-30
IL184365A0 (en) 2007-10-31
KR20070114126A (ko) 2007-11-29
DOP2006000009A (es) 2006-08-15
US20060154940A1 (en) 2006-07-13
US7425630B2 (en) 2008-09-16
CR9224A (es) 2007-10-23
AR052557A1 (es) 2007-03-21
HN2006001493A (es) 2010-08-19
WO2006076455A2 (en) 2006-07-20
PE20061118A1 (es) 2006-10-13
EP1838713A2 (en) 2007-10-03
BRPI0606115A2 (pt) 2009-06-02
CA2593345A1 (en) 2006-07-20
WO2006076455A8 (en) 2006-11-02
CN101142216A (zh) 2008-03-12
TW200637865A (en) 2006-11-01
GT200600011A (es) 2006-08-10
EA200701500A1 (ru) 2007-12-28
JP2008526975A (ja) 2008-07-24
PA8659701A1 (es) 2006-09-08
ZA200705279B (en) 2008-11-26
MX2007008381A (es) 2007-09-07
AU2006204940A1 (en) 2006-07-20
WO2006076455A3 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
NO20074052L (no) Prosesser for a fremstille pyrazol[3,4-D]pyrimidinetere
WO2008012227A8 (en) Pyrazoles as glucokinase activators
WO2008070692A8 (en) Bicyclic compounds and use as antidiabetics
TW200637845A (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
PL378295A1 (pl) Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu glukozy oraz profilaktyka i leczenie zaburzeń tego metabolizmu
MY157911A (en) Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
MX2009010047A (es) Compuestos quimicos.
MX2009010045A (es) Compuestos quimicos.
TW200637844A (en) Processes for preparing aromatic ethers
WO2006127898A3 (en) (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use
NO20074872L (no) Pyrazoler
WO2009005677A3 (en) Antiviral compounds
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
WO2009014910A3 (en) N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders
TW200745121A (en) Chemical compound
NO20080372L (no) Pyrazolderivater som teraputiske midler
NO20065936L (no) Sulfonyletylfosfordiamidater for anvendelse ved behandling av cancer.
JO2749B1 (en) Indole-2-Wen derivatives bilaterally substituted at position 3, their preparation and therapeutic application
DK2185561T3 (da) Derivater af 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6-carboxamid og 2,3,4,5-tetrahydroprrolo(1,2-a)-diazepin-7-carboxamid, fremstilling deraf og terapeutisk anvendelse deraf
WO2008041176A3 (en) Process for the preparation of form i and form ii of ritonavir
UA87026C2 (ru) СПОСОБ ПОЛУЧЕНИЯ ПИРАЗОЛО[3, 4-d]ПИРИМИДИНОВЫХ ЭФИРОВ
WO2006113237A3 (en) Cd39l3 and its role in diabetes
WO2007034183A3 (en) Process for the preparation of 4-aminopyrazole derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application